No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
Voyager Therapeutics: A Buy Rating on the Back of Strategic Advancements and a Promising Alzheimer's Candidate
Express News | Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
Express News | Voyager Aims for Initial Tau Pet Imaging Data by Second Half of 2026
Express News | Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of Vy-Tau01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics: A Strong Buy on Promising Pipeline and Financial Stability